TBPH Relative Valuation
TBPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TBPH is overvalued; if below, it's undervalued.
Historical Valuation
Theravance Biopharma Inc (TBPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -53.40. The fair price of Theravance Biopharma Inc (TBPH) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 18.70 USD , Theravance Biopharma Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：18.70
Fair
Undervalued
26.88
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Theravance Biopharma Inc. (TBPH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -87.42. The thresholds are as follows: Strongly Undervalued below -827.54, Undervalued between -827.54 and -457.48, Fairly Valued between 282.63 and -457.48, Overvalued between 282.63 and 652.69, and Strongly Overvalued above 652.69. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
208.17
EV/EBIT
Theravance Biopharma Inc. (TBPH) has a current EV/EBIT of 208.17. The 5-year average EV/EBIT is -8.02. The thresholds are as follows: Strongly Undervalued below -74.03, Undervalued between -74.03 and -41.03, Fairly Valued between 24.99 and -41.03, Overvalued between 24.99 and 57.99, and Strongly Overvalued above 57.99. The current Forward EV/EBIT of 208.17 falls within the Strongly Overvalued range.
8.49
PS
Theravance Biopharma Inc. (TBPH) has a current PS of 8.49. The 5-year average PS is 9.63. The thresholds are as follows: Strongly Undervalued below 0.63, Undervalued between 0.63 and 5.13, Fairly Valued between 14.13 and 5.13, Overvalued between 14.13 and 18.63, and Strongly Overvalued above 18.63. The current Forward PS of 8.49 falls within the Historic Trend Line -Fairly Valued range.
9.13
P/OCF
Theravance Biopharma Inc. (TBPH) has a current P/OCF of 9.13. The 5-year average P/OCF is -11.94. The thresholds are as follows: Strongly Undervalued below -99.17, Undervalued between -99.17 and -55.56, Fairly Valued between 31.68 and -55.56, Overvalued between 31.68 and 75.30, and Strongly Overvalued above 75.30. The current Forward P/OCF of 9.13 falls within the Historic Trend Line -Fairly Valued range.
45.26
P/FCF
Theravance Biopharma Inc. (TBPH) has a current P/FCF of 45.26. The 5-year average P/FCF is -9.83. The thresholds are as follows: Strongly Undervalued below -100.62, Undervalued between -100.62 and -55.22, Fairly Valued between 35.57 and -55.22, Overvalued between 35.57 and 80.96, and Strongly Overvalued above 80.96. The current Forward P/FCF of 45.26 falls within the Overvalued range.
Theravance Biopharma Inc (TBPH) has a current Price-to-Book (P/B) ratio of 4.07. Compared to its 3-year average P/B ratio of 2.27 , the current P/B ratio is approximately 79.15% higher. Relative to its 5-year average P/B ratio of 0.43, the current P/B ratio is about 843.78% higher. Theravance Biopharma Inc (TBPH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.42%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.14% , the current FCF yield is about -100.00% lower.
4.07
P/B
Median3y
2.27
Median5y
0.43
25.44
FCF Yield
Median3y
-6.42
Median5y
-14.14
Competitors Valuation Multiple
The average P/S ratio for TBPH's competitors is 0.41, providing a benchmark for relative valuation. Theravance Biopharma Inc Corp (TBPH) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 18.51%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TBPH increased by 98.72% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 10.59 to 32.23.
The secondary factor is the Revenue Growth, contributed 18.51%to the performance.
Overall, the performance of TBPH in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Theravance Biopharma Inc (TBPH) currently overvalued or undervalued?
What is Theravance Biopharma Inc (TBPH) fair value?
How does TBPH's valuation metrics compare to the industry average?
What is the current P/B ratio for Theravance Biopharma Inc (TBPH) as of Dec 05 2025?
What is the current FCF Yield for Theravance Biopharma Inc (TBPH) as of Dec 05 2025?
What is the current Forward P/E ratio for Theravance Biopharma Inc (TBPH) as of Dec 05 2025?